These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20891026)

  • 1. Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint.
    Padmanabhan SK; Dragalin V
    Biom J; 2010 Dec; 52(6):836-52. PubMed ID: 20891026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
    Polley MY; Cheung YK
    Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based approaches for time-dependent dose finding with repeated binary data.
    Benda N
    Stat Med; 2010 May; 29(10):1096-106. PubMed ID: 20082362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bayesian dose-finding design adapting to efficacy and tolerability response.
    Padmanabhan SK; Berry S; Dragalin V; Krams M
    J Biopharm Stat; 2012; 22(2):276-93. PubMed ID: 22251174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
    Hothorn LA; Wassmer G
    J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal design for dose response using beta distributed responses.
    Wu Y; Fedorov VV; Propert KJ
    J Biopharm Stat; 2005; 15(5):753-71. PubMed ID: 16078383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.
    Mandrekar SJ; Cui Y; Sargent DJ
    Stat Med; 2007 May; 26(11):2317-30. PubMed ID: 17016867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
    Li W; Fu H
    J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-stage design for dose-finding that accounts for both efficacy and safety.
    Dragalin V; Fedorov VV; Wu Y
    Stat Med; 2008 Nov; 27(25):5156-76. PubMed ID: 18680164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs based on the truncated product method.
    Neuhäuser M; Bretz F
    BMC Med Res Methodol; 2005 Sep; 5():30. PubMed ID: 16171518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive design method based on sum of p-values.
    Chang M
    Stat Med; 2007 Jun; 26(14):2772-84. PubMed ID: 17133651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose finding designs for continuous responses and binary utility.
    Fedorov VV; Wu Y
    J Biopharm Stat; 2007; 17(6):1085-96. PubMed ID: 18027218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Khan OA; Tselis A; Boster A
    Neurology; 2009 Jun; 72(24):2134; author reply 2134-5. PubMed ID: 19528523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.